Goal
The project aims to quantify the impact on 28-day mortality of different treatment decisions for community-onset and hospital-onset infections.
Lead
Cherry Lim and Ben Cooper – Centre for Tropical Medicine and Global Health at the University of Oxford
What we did
Two independent target hypothetical sequential trials were designed for community-onset and hospital-onset infections. Patients in the hypothetical trials were to be randomised to either continue antibiotics from the same AWaRe group as the ongoing treatment or switch to another AWaRe group. Electronic health records of patients admitted in Oxfordshire hospitals between 2015 and 2022 were used to emulate these two target trials. Multiple sensitivity analyses were performed.
Key learnings
Our results suggested that for the continued and switching strategies explored, continuing on the same AWaRe group of empiric antibiotic treatment for at least 3 days would give the least risk of 28-day in-hospital mortality, however we cannot rule out residual confounding.
Outputs
Funder
The Wellcome Trust